It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Many asthma patients remain uncontrolled despite guideline-based therapies. We examined real-life asthma control in Japanese patients prescribed with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA). Patients (≥12 years) with ≥2 asthma diagnoses, newly initiated on medium-/high-dose ICS/LABA (Japanese asthma guidelines), from 01 April 2009 to 31 March 2015 were included, using Japan Medical Data Center Claims Database. Primary objective: proportion of patients with uncontrolled asthma in the year following ICS/LABA initiation. Secondary objectives: predictors of uncontrolled asthma and healthcare resource utilization. In medium-dose (N = 24,937) and high-dose (N = 8661) ICS/LABA cohorts, 23% and 21% patients, respectively, were uncontrolled. Treatment step up and exacerbation were most common indicators of uncontrolled asthma. Predictors of uncontrolled asthma, analyzed by multivariable Cox model, included systemic corticosteroid use, exacerbation history, comorbidities, and being female. In both cohorts, healthcare resource utilization was higher in patients with uncontrolled asthma. Over 20% patients with persistent asthma who initiated medium- or high-dose ICS/LABA were uncontrolled, highlighting unmet need for novel therapies in these patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kagoshima University, Department of Pulmonary Medicine, Kagoshima, Japan (GRID:grid.258333.c) (ISNI:0000 0001 1167 1801)
2 Novartis Pharma AG, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
3 Novartis Ireland Limited, Dublin, Ireland (GRID:grid.419481.1)
4 Novartis Pharma K.K. Tokyo, Tokyo, Japan (GRID:grid.418599.8)
5 Novartis Sverige AB, Kista, Sweden (GRID:grid.418599.8)
6 OptumRx, Dublin, Ireland (GRID:grid.418599.8)
7 Kochi University, Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi, Japan (GRID:grid.278276.e) (ISNI:0000 0001 0659 9825)
8 Osaki Citizen Hospital, Osaki, Japan (GRID:grid.459827.5) (ISNI:0000 0004 0641 2751)